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Abstract
Malaria caused by Plasmodium falciparum is responsible for nearly 1 million deaths annually. Although much progress has
been made in the recent past, the development of a safe, effective and affordable malaria vaccine has remained a challenge.
A vaccine targeting sexual stages of the parasite will not only reduce malaria transmission by female Anopheles mosquitoes,
but also reduce the spread of parasites able to evade immunity elicited by vaccines targeting pre-erythrocytic and
erythrocytic asexual stages. We focused our studies on Pfs48/45, a protein expressed in the sexual stages developing within
an infected person and one of the most promising transmission-blocking vaccine targets. Functional immunogenicity of
Pfs48/45 protein requires proper disulfide bond formation, consequently evaluation of the immunogenicity of recombinant
full-length Pfs48/45 has been hampered by difficulties in expressing properly folded protein to date. Here we present a
strategy involving harmonization of codons for successful recombinant expression of full length Pfs48/45 in Escherichia coli.
The purified protein, designated CH-rPfs48/45, was recognized by monoclonal antibodies directed against reduction-
sensitive conformational epitopes in the native protein. Immunogenicity evaluation in mice revealed potent transmission
blocking activity in membrane feeding assays of antisera elicited by CH-rPfs48/45 formulated in three different adjuvants,
i.e. Alum, Montanide ISA-51 and complete Freund’s adjuvant. More importantly, CH-rPfs48/45 formulated with Montanide
ISA-51 when administered to nonhuman primates (Olive baboons, Papio anubis) resulted in uniformly high antibody
responses (ELISA titers .2 million) in all five animals. Sera from these animals displayed greater than 93% blocking activity
in membrane feeding assays after a single immunization, reaching nearly complete blocking after a booster dose of the
vaccine. The relative ease of expression and induction of potent transmission blocking antibodies in mice and nonhuman
primates provide a compelling rationale and basis for development of a CH-rPfs48/45 based malaria transmission blocking
vaccine.
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Introduction
Based on most recent estimates from the WHO, worldwide, there
were an estimated 247 million malaria cases among 3.3 billion
people at risk living in 109 countries [1]. Infections caused by P.
falciparum and P. vivax account for more than 90% of global malaria
burden; the former being responsible for nearly all the deaths due to
malaria, nearly a million deaths of children under 5 years [2]. Some
of the current efforts against malaria include increasing use of
insecticide treated bed nets and use of combination drugs to tackle
theproblemassociatedwithdrug resistance[3,4].Theemergenceof
drug-resistant strains over the last 4 decades has emphasized the
necessity of new control strategies. In this regard, the development
of a safe and effective malaria vaccine is expected to play important
and critical role in controlling malaria [5]. Such vaccine
development efforts havefocusedon candidateantigens represented
in the pre-erythrocytic, erythrocytic and sexual stages of the
parasite. Currently, the only vaccine advanced in clinical develop-
ment, RTS,S, has shown partial protection against infection and
disease severity in several clinical trials [6,7].
Immunity against the sexual stages of the parasite offers an
effective way to reduce or stop malaria transmission and in that
respect offers the greatest promise towards the goal of progressively
eliminating malaria from endemic countries. A transmission
blocking vaccine (TBV) [8] specifically targeting the sexual
development of the parasite in the mosquito vector may elicit
immunity which can effectively block transmission of the parasite
from invertebrate mosquito vector to vertebrate host. Transmission
of malaria depends upon the presence of infectious male and female
gametocytes in the peripheral blood of infected persons and
successful ingestion of these gametocytes by Anopheles mosquitoes.
Soon after ingestion, exflagellation occurs within the mosquito
midgut, and emergent male gametes fertilize female gametes,
resulting in the formation of zygotes. The zygotes undergo
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traverse the midgut epithelium and develop into oocysts resulting
in the production of infective sporozoites. Finally the sporozoites are
released into the hemocoel, invade the salivary glands and are
transmitted to vertebrate hosts during subsequent blood feeding [9].
The targets of transmission blocking antibodies include pre-
fertilization antigens (Pfs230 and Pfs48/45) expressed in the
circulating gametocytes and post-fertilization antigens (Pfs25 and
Pfs28) expressed during mosquito stage ookinete development
[10]. Unlike Pfs25 and Pfs28, pre-fertilization antigens are also
targets of the natural immune response and thus immunity
induced by a vaccine based on any of these antigens will have the
added benefit of natural boosting of immunity. To date, only Pfs25
and Pvs25 (P. vivax homolog of Pfs25) have undergone limited
Phase I clinical trials with marginal success [11,12]. So far it has
not been possible to evaluate any of the pre-fertilization antigens as
vaccines simply because they have not been available in sufficient
quantity and proper protein conformation.
Our choice of pre-fertilization antigen Pfs48/45 (encoded by a
1347 bp single open reading frame) over Pfs230 (encoded by a
much larger 9.4 kb ORF) was based primarily on the size of the
recombinant protein to be expressed. Both are cysteine-rich
polypeptides (16 residues in Pfs48/45 and 70 in Pfs230) and due to
the conformational nature of target epitopes it has not been
possible to further delineate functional protein domains for vaccine
development [13]. Additionally, targeted gene disruption studies
have shown that Pfs48/45 plays a critical role in male gamete
fertility, an important aspect of the sexual reproduction success of
the parasite [14]. Analysis of immune human sera in endemic
areas has also suggested a strong correlation between naturally
present anti-Pfs48/45 antibodies and transmission reducing
activity of those human sera; thus making it a key candidate for
vaccine development [15]. However, efforts to produce full length
recombinant Pfs48/45 in a functional conformation have largely
remained unsuccessful. In a recent study, an approach that
involved co-expression of a truncated version of C-terminal
fragment of Pfs48/45 fused with a large fusion partner maltose
binding protein (MBP) along with four periplasmic folding
catalysts DsbA, DsbC, FkpA and SurA resulted in correctly folded
truncated product which produced high titers of transmission-
reducing antibodies in immunized BALB/c mice [16]. In this
recombinant expression approach periplasmic targeting and
folding into functional conformation of expressed Pfs48/45
protein was strictly dependent upon fusion with MBP as a carrier
protein and protein folding was catalyzed by four chaperons co-
expressed in the host, respectively.
In this study, we employed an approach that harmonizes codon
usage frequency of the target gene with those of the expression host
for heterologous expression of protein. Basic studies on regulation of
proteinexpressionhaveshownthatsynonymouscodonsubstitutions
from infrequent to frequent usage in regions where mRNA
translation occurs relatively slowly can be detrimental to protein
expression and stability [17]. On the other hand, codon
substitutions introducing rare codons in the regions containing
high frequency codons can lead to erroneous protein conformation
[18]. Taking these concepts into account, an algorithm termed
‘‘codon harmonization’’ [19] was developed where synonymous
codons from E. coli were selected that closely resemble the codon
usage of native Pfs48/45 gene, including regions coding ‘link/end’
segments of proteins in P. falciparum. This approach harmoniously
mimics the translation rate of protein expression in native host by
allowing the translation machinery to pause at exactly the same
positions in E. coli as in P. falciparum and as presented in this article
yielded expression of correctly folded Pfs48/45 in E.coli. The
method of codon harmonization has already proved to be successful
in facilitating production of several GMP grade malaria vaccines for
ongoing vaccine trials [20,21]. This study reports for the first time
the efficient and successful expression of full length TBV candidate
Pfs48/45 in high yields and appropriate conformation. The
recombinant Pfs48/45 elicits potent malaria transmission blocking
antibodies in mice and non human primates (Olive baboons, Papio
anubis) and suggests a malaria TBVcould be developed based on the
CH-rPfs48/45 antigen.
Results
Expression and purification of correctly folded Pfs48/45
The native sequence of Pfs48/45 (accession number AF356146)
lacking N-terminal signal sequence (amino acid residues 1–27) and
C-terminal anchor (amino acid residues 428–448) was converted
to ‘codon harmonized’ sequence designed for expression in E. coli.
The amino acid sequence reported under AF356146 differs from
that of Z22145 (NF54) by C32Y, K33N, T72N, K253N and
N254K substitutions. The A/T contents of Pfs48/45 sequence
before and after codon harmonization were 75% and 56%,
respectively. The codon harmonized Pfs48/45 sequence contain-
ing a sequence tag coding for 6 x histidines at the 59 end was
synthesized by Retrogen Inc., cloned into the pET (K
2) expression
vector [19] and expressed in BL21 (DE3) cells [Fig. 1a]. Initial
attempts to induce the cells with IPTG indicated that the
expressed protein might negatively impact the growth of E.coli.
To overcome the toxicity of expressed protein, we modified
expression strategy to slow down protein expression by growing
the cells at 30uC in Luria-Bertani growth medium containing 1%
glucose and induction with 0.1 mM IPTG for 3 h, which resulted
in highly efficient induction of protein in the cell lysate at 50 kDa
[Fig. 1b, left panel, encircled]. The cell lysate when treated with b-
ME to reduce the disulphide bonds in the protein, showed slower
electrophoretic mobility of the induced Pfs48/45 protein [Fig. 1b,
right panel, encircled]. A similar observation was made with the
native form of the protein on the gametocyte surface [22,23].
Western blot analysis of cell lysates either untreated or after
treatment with 0.5% sarcosyl revealed that the recombinant protein
was insoluble in the absence of sarcosyl detergent (data not shown),
and hence the treatment with ionic detergent was required to
facilitate extraction of the protein from the pellet. To selectively
enrich expressed Pfs48/45, the lysate was first treated with non-
ionic detergent Tween-80 to remove any soluble bacterial proteins
followed by treatment with 0.5% sarcosyl in PBS [Fig. 1c]. This
sequential detergent extraction resulted in partial solubilization of
the expressed protein which could be further purified using Ni
2+-
NTA-Agarose beads (QIAGEN) by elution using imidazole (1 M),
yielding ,3 mg purified protein/gof wet cell pellet[Fig. 1d,e].The
yield of purified CH-rPfs48/45 in 7 independent purifications
varied between 15 and 25 mg per liter of induced culture. The
conformational characterizationof the expressedprotein designated
CH-rPfs48/45 was achieved using a mAb IIC5-B10 [22], which
recognizes a conformational reduction-sensitive epitope in the
parasite derived native Pfs48/45. The mAb recognized the non-
reduced form of CH-rPfs48/45 yielding 3 immunoreactive bands at
,50 kDa of the gel [Fig. 1f, lane 1]. In addition to these monomeric
forms, purified CH-rPfs48/45 protein preparations consistently
revealed the presence of a higher molecular weight band at
,98 kDa, presumed to be a dimer. When a similar Western blot
analysis was carried out with CH-rPfs48/45 after reduction prior to
SDS-PAGE, the mAb rather unpredictably showed recognition of a
single band around 65–68 kDa [Fig. 1f, lane 2]. Previous
biosynthetic metabolic labeling studies had established that
Transmission Blocking Vaccine
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doublet migrating in the region of 45 and 48 kDa) coalesces into a
single protein band of ,68 kDa when analyzed by SDS-PAGE
after reduction [23]. On the other hand, the same mAb strictly
recognized only the non-reduced form of native Pfs48/45 in the
gametocytes and gametes in Western blot analysis [24]. While the
reasons for the totally unexpected recognition of reduced form of
CH-rPfs48/45 are not so obvious, a possible interpretation may be
that the functional target epitope of blocking antibodies might be
conformationally more stable in the CH-rPfs48/45, and therefore
not affected by the reduction conditions employed.
Evaluation of functional immunogenicity of CH-rPfs48/45
in mice in different adjuvant formulations
The immunogenicity of CH-rPfs48/45 was assessed in three
different adjuvant formulations: CFA, water-in-oil emulsion using
Montanide ISA-51 and Aluminium hydroxide. Figure 2a shows
the IgG titer 2 weeks after the 2
nd boost in CFA group and 2 weeks
after the 3
rd boost in Alum and Montanide ISA-51 groups.
Although CFA is unsuitable for human vaccines, this formulation
resulted in the highest antibody titer ranging from 3610
5 to
.1610
6 [Fig. 2a, top panel]. However, all mice immunized with
CH-rPfs48/45 in the other two adjuvant formulations also showed
high antibody titer, the range being ,70,000 to more than
100,000 in both Montanide ISA-51 and Alum formulations
[Fig. 2a, middle and bottom panels]. We also tested sera for IgG
isotype distribution and all four subtypes (IgG1, IgG2a, IgG2b,
IgG3) were more or less equally represented in sera from mice
immunized with CFA formulation, [Fig. 2b, top panel]. On the
other hand, IgG1 and to a lesser extent IgG2 were the dominant
subtype in Montanide ISA-51 formulation [Fig. 2b, middle panel].
The overwhelming presence of IgG1 and negligible amount of
Figure 1. Purification and characterization of CH-rPfs48/45. (a) Schematic representation of amino acid residues in the recombinant protein
expressed. First 16 amino residues at the N-terminus contain 6 x Histidine residues and a short linker to allow affinity purification of the protein. The
sequenceofPfs48/45beginswithasparagine(N)atthe28positionandendswithserine(S)at427positioninthenativePfs48/45sequence.(b)Induction
profile of CH-rPfs48/45. The cells were induced with 0.1 mM IPTG for 3 h and lysed by sonication. Lysates of uninduced and induced cells either non-
reduced (left panel), or reduced (treated with 10 mM 2-mercaptoethanol, right panel) were run on SDS-polyacrylamide gel and stained with Coomassie
stain. Lane 1; Protein molecular weight marker; lane 2, uninduced cell lysate; lane 3, induced cell lysate. The induced protein band in both non-reduced
and reduced gels are encircled for easy recognition. (c) Flow diagram of various major steps including differential detergent extractions used for protein
purification. (d)Western blot analysis for the presence of CH-rPfs48/45 at each step of detergentextractionusing anti-His mAb. Lane 1,lysate pellet; lane
2, lysate supernatant; lane 3, 1% Tween-80 pellet; lane 4, 1% Tween-80 supernatant; lane 5, 0.5% sarcosyl pellet; lane 6, 0.5% sarcosyl supernatant. (e)
Western blot analysis of purified CH-rPfs48/45 using anti-His mAb. Lane 1, eluate from Ni-NTA column; lane 2, dialyzed CH-rPfs48/45. (f) Recognitiono f
CH-rPfs48/45 by conformation specific mAb IIC5B10. Lane 1, non-reduced CH-rPfs48/45; lane 2, reduced CH-rPfs48/45.
doi:10.1371/journal.pone.0006352.g001
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panel].
We also tested individual mouse sera for their ability to
recognize the native Pfs48/45 protein in gametocyte extracts in
both reduced and non-reduced form in Western blot analysis.
Polyclonal antisera against CH-rPfs48/45 recognized a combina-
tion of reduction-sensitive as well as reduction-insensitive epitopes
in Pfs48/45 in the parasites. Sera from mice immunized with CFA
and ISA-51 formulations recognized the native non reduced
protein (48/45 kDa), however, the sera from mice immunized
with alum formulation revealed recognition of 48/45 kDa protein
and also a protein ,98 kDa[Fig. 3a, left panel]. The reduced form
of the native protein was recognized by all of the aforementioned
sera at ,64 kDa[Fig. 3a, right panel]. As previously demonstrated
[24] the mAb IIC5B10 reacted only with nonreduced native
parasite antigen. The ability of the anti-CH-rPfs48/45 sera to
recognize the native form of the protein was further tested by live
immunofluorescence assay (IFA) using live extracellular gametes.
Figure 3b shows an example of strong gamete surface reactivity
typical of that observed for sera from mice immunized with CH-
rPfs48/45 in all three adjuvant groups.
To assess the functionality of the immunized sera, they were
tested for transmission blocking activity in mosquitoes in
membrane feeding assays (MFA) [10]. All the mice sera in the
three adjuvant groups showed a strong (.98% reduction in the
number of oocysts) transmission blocking activity at 1:2 dilution
[Table 1] as compared to corresponding pre-immune sera.
Geometric mean oocyst numbers per midgut in the presence of
pooled pre-immune sera of mice immunized in various adjuvant
formulations and tested at different dilutions ranged between 10.4
and 16.7. The decrease in oocyst number/midgut by each
immune sera was significant (P,0.02, Mann-Whitney test).
The transmission blocking effect was dependent upon the
antibody dose as revealed by a gradual decrease with increasing
Figure 2. (a) ELISA analysis of CH-rPfs48/45 immunized individual mouse sera in three different adjuvant formulations: Complete Freund’s adjuvant
(top panel), Montanide ISA-51 (middle panel), and Alum (bottom panel). All the results are representative of three independent experiments. Pooled
pre-immune sera + 3SD are shown by broken lines. ELISA OD405 values for individual mice are shown; mouse 1 (filled triangle), mouse 2 (open
square), mouse 3 (filled square), mouse 4 (open circle), mouse 5 (filled circle). (b) Analysis of anti-Pfs48/45 IgG isotype distribution in individual mouse
sera: IgG1 (filled columns), IgG2a (hatched columns), IgG2b (stippled columns), IgG3 (blank columns).
doi:10.1371/journal.pone.0006352.g002
Transmission Blocking Vaccine
PLoS ONE | www.plosone.org 4 July 2009 | Volume 4 | Issue 7 | e6352sera dilutions. Sera from mice immunized with CH-rPfs48/45
vaccine in CFA and Montanide ISA-51 formulations as compared
to Alum appeared to be relatively more potent blockers as
apparent from the stronger transmission blocking activities at 1:8
dilution of sera in MFA.
Evaluation of functional immunogenicity of CH-rPfs48/45
in non human primates (Olive baboons)
Backed by strong functional immunogenicity of CH-rPfs48/45
in three different adjuvant formulations in mice, we next evaluated
CH-rPfs48/45 vaccine in nonhuman primates (Papio anubis, Olive
baboons). The vaccine trial in baboons was approved by the
institutional and scientific review committee of the Institute of
Primate Research with a protocol #19/10/2007.
A group of 5 baboons (ranging 7.6 to 12.2 kg in body weight)
were immunized with 50 mg of CH-rPfs48/45 in Montanide ISA-
51, water-in-oil emulsion. Our choice of the adjuvant for these
studies was dictated, in part, by the fact that the adjuvant has
already been in use as an investigational adjuvant in clinical trials
in humans [25] and that the CH-rPfs48/45 vaccine formulated in
Montanide ISA-51 was strongly effective in murine immunization
studies (above). The vaccine, dose, route and schedules selected
were based on experience with numerous other malaria vaccine
trials in nonhuman primates [26,27,28]. In our studies the vaccine
was delivered through the intramuscular route (quadriceps, two
sites) and boosted twice with the same dose of protein at 4 and 12
weeks post primary immunization [Fig. 4a].
To evaluate the immunogenicity of CH-rPfs48/45 in baboons,
blood samples were collected from the immunized animals and
assessed by ELISA. All, except one animal (Pan 3275), responded
strongly after the primary immunization showing more than
8610
4 IgG titers 1 month after primary immunization. The titers
increased to .1 million, 1 month after the first dose of booster,
even in the case of the single primary dose unresponsive animal
[Fig. 4b], reaching an antibody titer of more than 2 million
following the second booster injection. We also tested the IgG
subtypes with various bleeds. Three out of five animals showed
predominantly IgG1 compared to IgG2, and for the other two
animals, the reverse was the case [Fig. 4c]. IgG3 was totally absent
from immunized sera in all the bleeds tested.
Mosquito MFA showed strong transmission blocking activity by
all animals for various bleeds obtained at different time points post
immunization [Table 2]. Even after primary immunization, the
sera (at 1:2 dilution) were capable of impressive transmission
blocking with more than 93% average reduction in the number of
oocysts in comparison to pre-immune sera of corresponding
animal. Pre-immune sera from each animal were used as a
measure of 100% transmission for the corresponding test sera. Pre-
immune serum from one animal (Pan 3275) exhibited ,30%
reduced transmission when compared with the pre-immune sera of
other four baboons. It is possible that natural infection by other
Plasmodium-like parasites, such as Enteropoides and Hepatocystis spp
might elicit partly cross-reactive and inhibitory activity. The
average transmission blocking activity increased to greater than
97% in all the animals after a booster dose. In order to titrate the
Figure 3. Recognition of native Pfs48/45 in P. falciparum gametocyte extract. (a) Western blot analysis with non-reduced (left panel) or
reduced (right panel) P. falciparum gametocyte extract against serum of individual mouse immunized with either CFA or ISA-51 or alum formulation.
Stage V gametocyte extract was run either in non-reduced or reduced (10 mM 2-mercaptothanol) form in SDS-PAGE and transferred to nitrocellulose
membrane. Mice sera were allowed to react at 1:1000 dilution for 1 h at 22uC. HRP-conjugated anti-mouse IgG at 1:10000 dilution was used as
detection antibody and was developed using ECL substrate. Lane 1, mAb IIC5B10; lane 2, one representative mouse serum immunized in CFA; lane 3,
one representative mouse serum immunized in Montanide ISA-51; lane 4, one representative mouse serum immunized in alum formulation. The
figure is assembled from separate experiments. (b) Mouse sera (1:1000 dilution) were tested by live immunofluorescence assays as described under
materials and methods.
doi:10.1371/journal.pone.0006352.g003
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further tested the sera obtained one month after the second boost
at various dilutions (1:4, 1:8, 1:16) in MFA. While exhibiting
strong blocking activity at 1:4 and 1:8 dilutions, the sera at 1:16
dilution were still able to reduce transmission (ranging from 74%
to 86%).
After the second booster dose, all five animals were bled at
monthly intervals and sera analyzed for antibody titers by ELISA
and functional transmission blocking activity in MFA. As shown in
figure 5, high antibody titers and high transmission blocking
activities were maintained for more than 7 months suggesting
further long lasting nature of immune responses elicited by CH-
rPfs48/45 in nonhuman primates.
Discussion
Together our data report for the very first time the expression of
full length soluble recombinant Pfs48/45 protein in proper
conformation with high yield following application of the codon
harmonization approach for recoding gene sequences. The
recombinant protein (designated CH-rPfs48/45) showed remark-
able immunogenicity and functional activity, i.e. transmission
blocking activity in mice immunized in the three adjuvant
formulations tested. Further significance of our results is reflected
by evidence from pre-clinical vaccine testing in nonhuman
primates. The vaccine revealed potent immunogenicity and
effective blocking activity even after a single immunization which
became much stronger (approaching 100% reduction) after a
booster immunization. Ease of expression and purification of
protein at high yields, conformational folding and strong
immunogenicity of CH-rPfs48/45 in mice and non human
primates provide a much needed rationale for moving ahead with
the development of malaria TBV based on Pfs48/45 antigen.
Mosquito infection (oocyst load and percent infected mosquitoes)
in the presence of 4/5 pre-immune sera were comparable to those
obtained with normal human serum negative control.
Expression of P. falciparum proteins in heterologous hosts is
especially challenging due to high A/T content within protein
coding genes (.80%). All previous attempts to express properly
folded full length recombinant Pfs48/45 have remained unsuc-
cessful. In this study we employed a relatively recent approach of
codon harmonization to express Pfs48/45 in E. coli in a
functionally correct conformation. Whether similar adjustments
for relative codon usage can be employed for expressing other
transmission blocking antigens. i.e. Pfs230 and Pfs25 remains to be
seen. Another strict requirement for the development of a
transmission blocking vaccine is the production of proteins in
correctly folded conformation. Not only did we find a robust
expression of Pfs48/45 after codon harmonization of the coding
sequence, the purified protein was found to be in correct
conformation as revealed by Western blot analysis using
monoclonal antibodies directed against reduction-sensitive con-
formational epitopes. Curiously, the recombinant Pfs48/45 was
recognized by the same antibodies even after treatment with
reducing agents, suggesting that the target epitopes in the
expressed proteins are stable and not susceptible to reduction.
Further development of a transmission blocking vaccine based
on Pfs48/45 is supported by the observation that the purified
protein exhibited very strong and longer lasting functional
immunogenicity in baboons. The antibodies elicited by vaccina-
tion continued to effectively suppress, even 5–6 months after the
last booster immunization, infectivity (both oocyst burden and
percentage of mosquitoes infected) of P. falciparum gametocytes in
Anopheles mosquitoes. Previous studies have shown that Pfs48/45
proteins normally expressed in the erythrocytic gametocyte stage
of the parasite is also a target of partially effective natural immune
response. It has been hypothesized that a vaccine induced
response could be further boosted during natural infection and
thus help in maintaining higher antibody levels in the vaccinated
people. Strongly backed by our success, efforts are currently
underway to produce GMP grade Pfs48/45 for the development
of a vaccine formulation for clinical trial in humans.
A sustained transmission reduction will be essential to meet the
challenge of elimination of the malaria disease and perhaps even
complete eradication from various endemic countries, as contem-
plated in the goals of the global malaria action plan of the Roll
Back Malaria Partnership [29,30,31]. A vaccine targeting the
process of malaria transmission could greatly facilitate achieving
such a goal of progressive elimination of malaria.
Materials and Methods
Cloning, expression and purification of CH-rPfs48/45
The codon harmonized sequence of Pfs48/45 containing 6x
Histidines at N-terminal end was synthesized by Retrogen Inc. and
cloned into the expression vector pET(K2)i nE. coli BL21 (DE3)
competent cells (Invitrogen Corp.). The cells containing
pET(K
2)Pfs48/45 were grown overnight at 30uC in LB media
containing 1% glucose and 50 mg/ml Kanamycin. The overnight
culture was diluted 100 fold into 1 l culture in above mentioned
media and grown at 30uC with agitation until the OD600 of the
culture reached 1.00. The cells were then induced with 0.1 mM of
IPTGandgrownfor3 h at30uC.Thecellswerethen harvested and
Table 1. MFA with sera from mice immunized with CH-
rPfs48/45 formulated in CFA, Montanide ISA-51 or Alum.
Serum dilution
Animal no. 1:2 1:4 1:8
CFA
1 100.0 (0/20) 89.6 (8/20) 76.8 (18/33)
2 97.5 (14/41) 88.0 (7/16) 79.3 (24/38)
3 98.3 (7/28) 90.2 (4/15) 72.6 (16/34)
4 94.3 (12/22) 90.5 (9/26) 83.5 (21/42)
5 98.0 (9/30) 93.9 (6/20) 84.6 (15/28)
ISA 51
6 96.1 (5/15) 88.0 (16/23) 76.8 (12/19)
7 98.4 (2/12) 89.9 (11/20) 74.9 (10/17)
8 96.4 (7/18) 92.5 (12/22) 69.7 (16/22)
9 96.2 (7/15) 90.6 (15/25) 72.6 (11/18)
10 95.1 (10/20) 86.2 (10/17) 79.1 (12/19)
Alum
11 93.5 (11/24) 86.2 (14/30) 54.9 (21/29)
12 95.3 (9/26) 78.6 (16/24) 58.3 (14/20)
13 96.6 (12/31) 89.9 (6/15) 55.4 (15/22)
14 94.5 (7/16) 89.2 (9/17) 70.5 (16/26)
15 95.2 (5/16) 91.6 (6/16) 61.4 (16/23)
Individual mouse sera were tested for transmission blocking activity with
respect to corresponding pooled pre-immune sera. Data are represented as
percent transmission blocking activity (reduction in the number of oocysts per
mosquito midgut). Numbers within parenthesis represent total number of
infected mosquitoes/total number of mosquitoes dissected for each feed.
doi:10.1371/journal.pone.0006352.t001
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PLoS ONE | www.plosone.org 6 July 2009 | Volume 4 | Issue 7 | e6352Figure 4. Analysis of anti-Pfs48/45 antibody production by Olive baboons (Papio anubis). (a) Each animal was immunized with CH-rPfs48/
45 (50 mg in 0.25 ml endotoxin free PBS) formulated in Montanide ISA-51 (0.25 ml) in baboons, administered intra muscularly (quadriceps, two sites).
Schedules for immunization and bleeds are indicated and sera were stored at 220uC until shipped frozen from Kenya to Baltimore for ELISA and MFA.
The samples were shipped under an export permit CITES # 008101. (b) Anti-Pfs48/45 whole IgG titer at various time points analyzed by ELISA. Pre-
immune +3 x SD is shown by solid horizontal lines. ELISA readings with sera dilutions, 1 month post primary immunization (filled square), 1 month
post first boost (filled triangle) and 1 month post second boost (filled diamond) are shown with6SD for individual baboons (Pan 3104, Pan 3140, Pan
3163, Pan 3275, Pan 3313). (c) Distribution of anti-Pfs48/45 IgG1(solid diamonds) and IgG2 (open diamonds) subtypes in 1 month post primary
immunization sera (Dec 10), 1 month post 1
st boost (Jan 10), 1 month post 2
nd boost (Mar 06), and 3 months post 2
nd boost (May 05). Data are
presented as mean OD405 value6SD for individual baboon.
doi:10.1371/journal.pone.0006352.g004
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280uC for further processing. The frozen pellet was resuspended in
1x PBS (pH 7.4) at a pellet to buffer ration of 1:10 (w/v) and was
lysed by microfluidization (Model M110Y, Microfluidics). The
lysate was centrifuged at 24000 x g for 45 min at 4uC. The lysate
pellet was resuspended in 1x PBS containing 1% Tween-80 (final v/
v), extracted for 30 min at 22uC and centrifuged at 24000 x g for
30 min at 4uC. The pellet was resuspended in 1x PBS containing
0.5% Sodium Lauroyl Sarcosine (sarcosyl) (final v/v), extracted and
centrifuged as before. The supernatant was then passed through Ni-
NTA agarose column (QIAGEN) according to manufacturer’s
protocol. The protein was eluted as 1 ml fractions with 1 M
imidazole in 1x PBS as elution buffer. The protein was dialyzed
against 1x PBS (pH 7.4) containing 10% glycerol and 0.2% Tween-
80. Finally, the protein content was estimated using BCA
TM Protein
Assay kit (Pierce) and the endotoxin level in the protein was
measured using QCL-1000 Endpoint chromogenic LAL assay kit
(Lonza).
Characterization of CH-rPfs48/45
The CH-rPfs48/45 was characterized by Western blot analysis.
Briefly, samples from each purification step described above were
run on SDS-PAGE and transferred to nitrocellulose membrane
(Bio-Rad). The membrane was blocked overnight with 1x PBS
containing 5% non-fat dry milk and 0.1% Tween-20 (blocking
buffer) at 4uC. Following blocking, the membrane was washed
with 1x PBS containing 0.1% Tween-20 (wash buffer) and
incubated with either 6xHis mAb (Clontech) at 1:1000 dilution
[Fig. 1d, e] or IIC5B10 mAb (MR4) at 1:5000 dilution [Fig. 1f] for
1 h at 22uC. The membrane was washed 4x in wash buffer for
30 min at 22uC and incubated with HRP-conjugated anti-mouse
IgG mAb (GE Healthcare) at 1:10000 dilution in blocking buffer
for 1 h at 22uC. This was followed by washing 4 x with wash
buffer and ECL Plus chemiluminescent substrate (GE Healthcare)
was used as detection reagent.
Immunization of mice
Groups (n=5) of female BALB/c mice were immunized with
10 mg of CH-rPfs48/45 emulsified in either Complete Freund’s
Adjuvant (CFA) (Sigma) or Montanide ISA-51 (SEPPIC) or mixed
in aluminium hydroxide (Alhydrogel, Brenntag) adjuvant through
the intraperitoneal route. The mice immunized in CFA were
boosted at 4 week intervals twice with the same quantity of protein
in incomplete Freund’s adjuvant. Mice in the other adjuvant
Table 2. Transmission blocking activity of sera of different
bleeds at various time points from baboons immunized with
CH-rPfs48/45 in Montanide ISA-51.
Animals
Bleeds [% transmission blocking * (infected/total
mosquito)]
12/10/07 01/10/08 02/21/08 03/06/08 05/05/08
Pan 3104 92.8 (14/27) 95.7 (11/25) 98.7 (6/22) 97.7 (7/27) 98.8 (4/19)
Pan 3140 94.4 (14/21) 97.3 (12/28) 98.1 (6/24) 98.4 (7/23) 97.8 (7/18)
Pan 3163 98.1 (5/19) 98.5 (5/18) 97.3 (9/27) 97.3 (7/20) 97.4 (11/24)
Pan 3275 88.1 (12/20) 95.3 (11/25) 96.2 (10/28) 96.2 (9/23) 97.6 (5/22)
Pan 3313 91.8 (13/25) 97.0 (9/24) 94.7 (13/27) 97.8 (8/20) 95.3 (12/24)
*P,0.0001 (Mann-Whitney test).
MFA was done with sera collected on 12/10/2007 (1 mo post primary
immunization), 01/10/2008 (1 mo post 1
st boost, 02/21/2008 (15 d post 2
nd
boost), 03/06/2008 (1 mo post 2
nd boost), and 05/05/2008 (3 mo post 2
nd
boost). The geometric mean of oocyst numbers/midgut in the presence of
individual pre-immune sera were 22.24 (Pan 3104), 18.43 (Pan 3140), 22.1 (Pan
3163), 6.31 (Pan 3275), and 19.7 (Pan 3313), respectively. Numbers within
parenthesis represent total number of infected mosquitoes/total number of
mosquitoes dissected for each feed.
doi:10.1371/journal.pone.0006352.t002
Figure 5. Follow up of immune responses elicited by CH-rPfs48/45 in baboons. Analysis of anti-CH-rPfs48/45 IgG titers (open bars) and
percent transmission blocking activity (closed bars) upto 7 months post second boost in baboons. Results show mean antibody titer and mean
transmission blocking activity of 5 baboons +95% CI.
doi:10.1371/journal.pone.0006352.g005
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51 or Alum, respectively. Groups of control mice were immunized
with adjuvant formulations only. Blood was collected on day 0
(Pre-immune sera) and 4 weeks after primary immunization and 2
weeks post each boost for analysis of anti-Pfs48/45 IgG titer.
Immunization of Olive baboons (Papio anubis)
The vaccine trial in baboons was approved by the institutional
and scientific review committee of the Institute of Primate
Research with a protocol #10/10/2007. Because these animals
were trapped from their wild habitats, they were quarantined for 3
months and screened for the presence of any worms and
protozoan parasites and successfully treated appropriately, if
found infected, prior to initiating vaccination. Moreover, animals
were also screened by three intradermal tuberculin tests and found
to be negative for mycobacterial infections. Detailed hematological
tests were also administered on all five animals during their
quarantine period, just prior to and at the termination of the
vaccine trial, and were certified to be in excellent health at all time
points with no observable trial-related effects. A group of five
baboons (ranging 7.6 to 12.2 kg in body weight) were immunized
with 50 mg of CH-rPfs48/45 in Montanide ISA-51, water-in-oil
emulsion. The animals were sedated with ketamine (10 mg/kg) for
immunization and blood collection as per the schedule described
in Figure 4a.
ELISA
To assess the immunogenicity of CH-rPfs48/45, ELISA was
done. Briefly, Immulon-2 plates were coated with 1.5 mg/ml CH-
rPfs48/45 in carbonate-bicarbonate buffer (pH 9.6) overnight at
4uC, blocked with 5% milk in PBS and incubated with various
dilutions of sera at 37uC for 1 h. The plates were washed 5 times
in PBS-0.05% Tween-20 (PBST) followed by further incubation
with 1:10000 dilution of horseradish peroxidase conjugated anti-
mouse IgG antibody for 1 hour at 37uC. After washing in PBST,
wells were developed using ABTS substrate (Kirkegaard & Perry
Laboratories Inc.) for 20 min at 22uC and read at 405 nm in the
ELISA reader. Anti-Pfs48/45 whole IgG end point titers were
calculated from the highest group mean reciprocal serum dilution
greater than the mean plus 3 standard deviations OD reading of
pooled pre-immune sera in each assay. For IgG subtype analysis,
mouse sera were tested at a single 1: 1000 dilution. Various
isotype- specific secondary antibodies used were anti-mouse IgG1,
IgG2a, IgG2b and IgG3 from Kirkegaard & Perry Laboratories
Inc.
The ELISA with baboon sera was done following a similar
protocol and endpoint titers were calculated using the same
criteria. The secondary antibody was anti-human IgG1, IgG2, and
IgG3 conjugated to peroxidase (The Binding Site, Birmingham,
UK) and used at 1: 5000 dilution. Various sera were tested at
1:5000 dilution for IgG subclass analysis.
Parasite
Plasmodium falciparum NF54 parasites were maintained using
normal red blood cells and normal human serum (O+ve blood
group) as s described [32]. Stage V gametocytes were used in live
IFA studies and membrane feeding assays. To extract gametocytes
for Western blot analysis, the gametocyte culture was centrifuged
at 1000 x g for 5 min at 22uC. The RBC was lysed with 0.15%
saponin in PBS for 5 min at 22uC. The gametocytes were collected
after centrifugation at 1800 x g for 5 min and washed thrice in 1x
PBS. The gametocytes were resuspended in 25 mM Tris-Cl
(pH 7.5) containing 150 mM NaCl and 1x protease inhibitor
cocktail and kept frozen at -70uC till use.
Live IFA
The gametocytes were harvested from 19 day culture and
gametes were produced by incubating the gametocytes in
exflagellation buffer and purified by discontinuous Nycodenz
gradient centrifugation as described previously [33]. Extracellular
gametes were incubated at 4uC with 1:100 to 1:1000 dilution of
immune murine sera for 60 min. Parasites were washed 3 times
with 1% BSA in PBS followed by incubation with FITC-anti
mouse antisera (Alexa fluor 488), 1:500 dilution at 4uC for 60
minutes. After washing, cells were examined by upright fluorescent
Nikon E800 microscope (Japan) at 100X magnification.
Membrane Feeding Assay
To test the transmission blocking activity, the murine and
baboon immune sera were mixed with cultured P. falciparum
(NF54) stage V gametocytes, normal red blood cells and normal
human sera (donor blood group: O+) and fed to Anopheles gambiae
(starved for 5–6 hours) mosquitoes through water jacketed glass
membrane (stretched parafilm) feeders [10,33] Briefly, washed
human red blood cells and cultures containing stage V
gametocytes were resuspended to 66% hematocrit and 0.3%
gametocytemia in normal human serum and maintained through-
out at 37uC. Fifty microliters of various test sera (appropriately
diluted in normal human sera) were mixed with 150 mlo f
resuspended gametocyte mix and quickly added to individual
membrane feeders placed on top of cups containing starved
mosquitoes. The mosquitoes were allowed to engorge for 15 min.
The unfed mosquitoes were separated within 1 h of feeding and
blood fed mosquitoes (typically 25–30 per cup) were maintained in
the insectary at 26uC at 80% relative humidity. In certain cases the
total number of blood fed mosquites was less than 25 due to poor
feeding. Moreover, a small number of blood fed mosquites (less
than 5%) did not survive 9–10 days incubation period prior to
dissection. Midguts were dissected 9–10 days after blood meal for
enumeration of oocysts after staining with 1% mercurochrome.
Transmission blocking activity of individual sera was calculated as
percentage of reduction in oocyst number per midgut with test
sera in comparison with pooled pre-immune sera (pre-immune
murine or baboon sera was taken as allowing 100% transmission).
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